Literature DB >> 12360466

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years.

Martin Prince1, Amanda Chetwynd, Wendy Newman, Jane V Metcalf, Oliver F W James.   

Abstract

BACKGROUND & AIMS: Although several excellent studies have described the natural history of primary biliary cirrhosis, most were reported from tertiary referral centers. We examined the prognosis of primary biliary cirrhosis in a comprehensive geographically defined cohort.
METHODS: We followed up 770 primary biliary cirrhosis patients prevalent between January 1987 and December 1994 until death, transplantation, or censor on January 1, 2000, by interview and review of case notes and death certificates. Analysis of survival data was performed with Kaplan-Meier methods and Cox regression.
RESULTS: Median patient survival was 9.3 years from diagnosis. Patient age, alkaline phosphatase, albumin, and bilirubin at diagnosis independently predicted survival in Cox modeling. Prothrombin time and histologic stage did not independently affect survival. Observed survival was predicted well by this model and by the Mayo prognostic score (R2(M) = 0.37 and 0.18, respectively; R2(M) is a likelihood-based measure of the percentage information gain from the model due to covariates). Forty-two percent of deaths were caused by liver disease. Thirty-nine patients had liver transplantations by the censor date. Survival was much poorer than for an age- and sex-matched control population (standardized mortality ratio = 2.87 [1.73 excluding liver deaths]). The most common symptoms at diagnosis were pruritus (18.9%) and fatigue (21.0%). Twenty-six percent of patients developed liver failure by 10 years after diagnosis.
CONCLUSIONS: Although primary biliary cirrhosis is often now diagnosed at an early stage, the diagnosis still carries important prognostic implications. A significant proportion of patients develop liver failure, require transplantation, or die prematurely after this diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360466     DOI: 10.1053/gast.2002.36027

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  82 in total

Review 1.  Fatigue in primary biliary cirrhosis.

Authors:  Ghulam Abbas; Roberta A Jorgensen; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-11       Impact factor: 46.802

2.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  CD4+ CD25+ but not CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis.

Authors:  Dandan Wang; Huayong Zhang; Jun Liang; Zhifeng Gu; Qiang Zhou; Xiangshan Fan; Yayi Hou; Lingyun Sun
Journal:  Cell Mol Immunol       Date:  2010-08-23       Impact factor: 11.530

Review 4.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 5.  Pathogenesis of primary biliary cirrhosis.

Authors:  David E J Jones
Journal:  Gut       Date:  2007-07-19       Impact factor: 23.059

6.  38-year-old woman with abnormal liver enzymes and hyperlipidemia.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

Review 7.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

8.  MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.

Authors:  Tomohiro Katsumi; Masashi Ninomiya; Taketo Nishina; Kei Mizuno; Kyoko Tomita; Hiroaki Haga; Kazuo Okumoto; Takafumi Saito; Tooru Shimosegawa; Yoshiyuki Ueno
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

9.  Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment.

Authors:  Meri Koulentaki; Joanna Moscandrea; Philipos Dimoulios; Costas Chatzicostas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

10.  The value of antinuclear antibodies in primary biliary cirrhosis.

Authors:  Lixia Gao; Xinping Tian; Bin Liu; Fengchun Zhang
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.